Your browser doesn't support javascript.
loading
Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain.
Yousfan, Amal; Rubio, Noelia; Natouf, Abdul Hakim; Daher, Aamal; Al-Kafry, Nedal; Venner, Kerrie; Kafa, Houmam.
Afiliação
  • Yousfan A; Department of Pharmaceutics and Pharmaceutical Technology, Pharmacy Collage, Damascus University Syria.
  • Rubio N; Department of Chemistry and Materials, Imperial College London London SW7 2AZ UK.
  • Natouf AH; Department of Pharmaceutics and Pharmaceutical Technology, Pharmacy Collage, Damascus University Syria.
  • Daher A; Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria Damascus Syria hgkafa@gmail.com +963-940749813.
  • Al-Kafry N; Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria Damascus Syria hgkafa@gmail.com +963-940749813.
  • Venner K; Institute of Neurology, University College London Queen Square London WC1N 3BG UK.
  • Kafa H; Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria Damascus Syria hgkafa@gmail.com +963-940749813.
RSC Adv ; 10(48): 28992-29009, 2020 Aug 03.
Article em En | MEDLINE | ID: mdl-35520085
The use of nanoparticles (NPs) for intranasal (IN) drug delivery to the brain represents a hopeful strategy to enhance brain targeting of anti-epileptic drugs. In the present work, chitosan-lecithin NPs loaded with phenytoin (PHT), were prepared using the nano-precipitation method. The spherical nature of the NPs and their stability were confirmed using scanning and transmission electron microscopy, while the average dynamic size and zeta potential were measured using dynamic light scattering. The encapsulation efficiency of PHT was higher than 60% for all prepared NPs. Release studies showed that the amount of released PHT was directly related to the amount of chitosan used. The optimum preparation, L10Ci + was administered via the IN route, and the levels of PHT in the brain were measured in three-time points. Two experimental controls were given via the intraperitoneal (IP) and IN routes. The highest PHT amount reaching 1.01 ± 0.55% for L10Ci +, which was associated with a sustained release of PHT. These preliminary findings show that the IN delivery of PHT-loaded NPs is very promising for managing epilepsy. The direct nose-to-brain approach increases the safety margins of PHT, while the sustained release could improve patient compliance in a clinical setting.

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: RSC Adv Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: RSC Adv Ano de publicação: 2020 Tipo de documento: Article